AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-28 - Roadshow - Day 1

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

150.3 USD

Average target price

162.1 USD

Spread / Average Target

+7.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.09%	233B
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B
PFIZER, INC.	-11.77%	143B

Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:09 2024-04-26 am EDT			5-day change	1st Jan Change
11,988 ^GBX	-0.32%		+9.84%	+13.09%

03:26pm	ASTRAZENECA : DZ Bank sticks Neutral	ZD
03:11pm	ASTRAZENECA : UBS keeps a Sell rating	ZD

ASTRAZENECA : DZ Bank sticks Neutral	09:26am	ZD
ASTRAZENECA : UBS keeps a Sell rating	09:11am	ZD
ASTRAZENECA : Deutsche Bank remains Neutral	08:11am	ZD
ASTRAZENECA : Gets a Buy rating from Barclays	07:56am	ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight	07:43am	MT
Peel Hunt cuts ConvaTec to 'reduce'	04:34am	AN
THE FTSE 100 is on a roll	04:23am
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade	Apr. 25
FTSE 100 shakes off red-hot US inflation gauge	Apr. 25	AN
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
ASTRAZENECA : UBS maintains a Sell rating	Apr. 25	ZD
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	Apr. 25	MT
The specter of stagflation rears its ugly head again	Apr. 25
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	Apr. 25	DP
Sector Update: Health Care	Apr. 25	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	Apr. 25	MT
ASTRAZENECA : Jefferies sticks Neutral	Apr. 25	ZD
ASTRAZENECA : JP Morgan remains its Buy rating	Apr. 25	ZD
FTSE 100 hits high on offer for Anglo American	Apr. 25	AN
Transcript : AstraZeneca PLC, Q1 2024 Earnings Call, Apr 25, 2024	Apr. 25